Mexico City, Mexico — President Claudia Sheinbaum announced an investment of more than 21 billion pesos through seven projects. The projects will include drug production and clinical research to strengthen the country’s industry.
She reaffirmed that the goal of the Mexico Plan is to produce more than we consume as well as to increase and diversify exports.
“It is a comprehensive long-term project, the concept of sovereignty in the production of many things is very important, and what we are also looking for is that there is more production of medicines in Mexico.
“It is very important that production, development, research, and technological advancement and manufacturing take place here. The pharmaceutical industry, in particular, has enormous potential in Mexico,” she said.
Sheinbaum says Mexico is developing various research projects in the medical sector from public institutions and that one of the goals to produce medicines and active ingredients.
The aim is also to reduce the price of drugs as a result of strengthening national production and competition, in addition to the consolidated purchase of medicines by the health sector.
“It’s not just the investment. Some of them are providing raw materials for the production of medicines and the other is the link with research institutions for clinical studies that allow the development of medicines.
“The benefits not only remain in a private company, but also in Birmex and in public institutions.”
She says the Federal Commission for Protection against Sanitary Risks (Cofepris) is making progress in reducing processing times and procedures to benefit the industry and investments.
Health Secretary David Kershenobich Stalnikowitz emphasized that the announcement demonstrates the possibility of developing and industrially producing medicines in the country.
The Undersecretary of Sectoral Integration and Coordination of Medical Care Services of the Ministry of Health, Eduardo Clark García Dobarganes emphasized that the public sector’s purchasing power for medicines serves as a lever for various joint investment projects.
He announced the consolidated acquisition for 2027-2028 is in the process of being finalized.
The CEO of Abbot Mexico, Edgar Romero Bejarano, reported an investment of 3.5 billion pesos and the creation of 1,200 jobs by 2030.
By constructing new facilities covering 20,000 square meters , they will expand the production of medical devices for the diagnosis and treatment of heart rhythm disorders.
The CEO of Bristol Myers Squibb, Oswaldo Bernal Carmona, announced an investment of 1 billion pesos to strengthen clinical research and the implementation of local manufacturing processes in innovative therapies.
Luz Astrea Ocampo Gutiérrez, the CEO of Grupo Neolpharma, says they are investing 700 million pesos to install a plant in Toluca that will generate 250 direct and 900 indirect jobs to export to the United States, Canada, Europe and Japan.
The CEO of Opella Mexico, Luis Solares, announced the investment of 2.3 billion pesos to expand and modernize the Ocoyoacac plant and produce the new line of the antibiotic Enterogermina, which begins on July 22.
Kener Laboratories CEO Federico Prince Laris announced an investment of 5.36 billion pesos for the expansion of the plant in Toluca. It will be their second blood products plant, a joint venture with the federal government, and a biotechnology plant. Together, these projects will generate 3,500 direct and indirect jobs.
Liomont’s Director of Biotechnology and Vaccines, Sergio Valentinotti Marelli, explained that the investment of over 4 billion pesos over the next five years will allow the construction of an oral solids plant in the State of Mexico and the expansion of the plant dedicated to injectables for technological medicines and vaccines.
Also, in Mexico City they will expand the production plant for biopharmaceuticals and recombinant vaccines, as well as the construction of a plant for the synthesis and encapsulation of messenger RNA.
Paola Martorelli, Director of Corporate Affairs for Sanofi Latin America, referred to the possible investment of 2 billion pesos for the construction of a plant for first and second generation basal insulins and rapid insulin with technology transfer to Mexico.
The general manager of Pharma Bayer Mexico, Daniel Londero, spoke about the investment of 150 million pesos for 10 clinical trials in public and private institutions. Collectively, this company’s investments will result in more than 6 billion pesos in annual exports.
